 Debashis Ghosh
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1774 | 5.070 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 363 | 4.590 |
Why?
| | Models, Statistical | 44 | 2024 | 669 | 4.550 |
Why?
| | Leishmaniasis, Visceral | 16 | 2024 | 22 | 4.440 |
Why?
| | Algorithms | 41 | 2025 | 1704 | 4.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 767 | 3.400 |
Why?
| | Machine Learning | 10 | 2024 | 493 | 2.690 |
Why?
| | Computer Simulation | 36 | 2024 | 978 | 2.680 |
Why?
| | Computational Biology | 20 | 2025 | 644 | 2.640 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.260 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1276 | 2.220 |
Why?
| | Metabolomics | 9 | 2022 | 678 | 2.200 |
Why?
| | Biometry | 13 | 2011 | 70 | 2.130 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 1043 | 1.850 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 18 | 1.780 |
Why?
| | Neoplasms | 25 | 2024 | 2671 | 1.720 |
Why?
| | Eye Proteins | 6 | 2016 | 92 | 1.710 |
Why?
| | Software | 15 | 2025 | 665 | 1.710 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.470 |
Why?
| | Regression Analysis | 13 | 2021 | 1024 | 1.470 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.450 |
Why?
| | Genomics | 12 | 2024 | 795 | 1.350 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 434 | 1.320 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1040 | 1.310 |
Why?
| | Models, Biological | 14 | 2021 | 1783 | 1.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1396 | 1.280 |
Why?
| | Humans | 196 | 2025 | 137585 | 1.220 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 431 | 1.150 |
Why?
| | Causality | 4 | 2022 | 126 | 1.140 |
Why?
| | Databases, Factual | 12 | 2024 | 1357 | 1.140 |
Why?
| | Biomarkers | 14 | 2021 | 4149 | 1.140 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1266 | 1.120 |
Why?
| | Insecticides | 4 | 2023 | 38 | 1.090 |
Why?
| | Insect Control | 4 | 2023 | 16 | 1.070 |
Why?
| | Biostatistics | 3 | 2014 | 18 | 1.070 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.060 |
Why?
| | Aromatase | 2 | 2019 | 32 | 1.010 |
Why?
| | Bangladesh | 13 | 2024 | 56 | 1.010 |
Why?
| | Survival Analysis | 12 | 2024 | 1325 | 1.000 |
Why?
| | Endemic Diseases | 2 | 2024 | 32 | 1.000 |
Why?
| | Natural Gas | 1 | 2025 | 24 | 0.930 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 31 | 0.920 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 186 | 0.920 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 289 | 0.900 |
Why?
| | Microscopy | 3 | 2023 | 152 | 0.870 |
Why?
| | Magnetoencephalography | 2 | 2021 | 149 | 0.870 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.860 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 258 | 0.850 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.830 |
Why?
| | Environmental Exposure | 3 | 2025 | 579 | 0.810 |
Why?
| | Genetic Association Studies | 5 | 2019 | 377 | 0.790 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1509 | 0.790 |
Why?
| | Models, Genetic | 11 | 2019 | 600 | 0.790 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 288 | 0.790 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2526 | 0.780 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.780 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 313 | 0.770 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 383 | 0.760 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.740 |
Why?
| | Connectome | 2 | 2021 | 86 | 0.740 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 35 | 0.720 |
Why?
| | Mass Spectrometry | 6 | 2022 | 739 | 0.720 |
Why?
| | Brain | 4 | 2024 | 2668 | 0.720 |
Why?
| | Brain Mapping | 2 | 2021 | 503 | 0.710 |
Why?
| | Housing | 2 | 2021 | 146 | 0.690 |
Why?
| | Nitriles | 1 | 2021 | 172 | 0.690 |
Why?
| | Endpoint Determination | 2 | 2011 | 77 | 0.680 |
Why?
| | Propensity Score | 4 | 2018 | 294 | 0.680 |
Why?
| | Cluster Analysis | 12 | 2024 | 499 | 0.670 |
Why?
| | Feasibility Studies | 2 | 2024 | 956 | 0.670 |
Why?
| | Phenotype | 12 | 2023 | 3196 | 0.650 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1050 | 0.640 |
Why?
| | Image Processing, Computer-Assisted | 7 | 2024 | 752 | 0.640 |
Why?
| | Placenta | 2 | 2019 | 750 | 0.630 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 158 | 0.630 |
Why?
| | Risk Assessment | 8 | 2020 | 3457 | 0.630 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 332 | 0.630 |
Why?
| | Learning | 1 | 2023 | 409 | 0.630 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 110 | 0.620 |
Why?
| | Databases, Genetic | 11 | 2021 | 237 | 0.620 |
Why?
| | Genetic Variation | 4 | 2019 | 991 | 0.610 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 125 | 0.600 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 182 | 0.600 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.580 |
Why?
| | Transcriptome | 2 | 2023 | 971 | 0.560 |
Why?
| | Glioma | 1 | 2022 | 395 | 0.560 |
Why?
| | Protein Conformation | 4 | 2015 | 934 | 0.560 |
Why?
| | Logistic Models | 12 | 2020 | 2074 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1477 | 0.550 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2111 | 0.550 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3284 | 0.550 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 97 | 0.530 |
Why?
| | Male | 73 | 2025 | 67762 | 0.530 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1738 | 0.520 |
Why?
| | Registries | 2 | 2024 | 2035 | 0.500 |
Why?
| | Markov Chains | 7 | 2017 | 126 | 0.480 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1946 | 0.480 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 155 | 0.480 |
Why?
| | Linear Models | 7 | 2018 | 849 | 0.470 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 476 | 0.460 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.460 |
Why?
| | Bayes Theorem | 7 | 2022 | 405 | 0.450 |
Why?
| | Female | 59 | 2025 | 73304 | 0.450 |
Why?
| | Case-Control Studies | 10 | 2025 | 3556 | 0.450 |
Why?
| | Protein Folding | 1 | 2016 | 280 | 0.450 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 89 | 0.440 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 395 | 0.440 |
Why?
| | Lupus Nephritis | 2 | 2025 | 63 | 0.440 |
Why?
| | Nerve Net | 3 | 2024 | 256 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 683 | 0.430 |
Why?
| | Statistics as Topic | 3 | 2025 | 307 | 0.420 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1081 | 0.420 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 116 | 0.410 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1431 | 0.410 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 172 | 0.400 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 168 | 0.400 |
Why?
| | India | 6 | 2023 | 195 | 0.400 |
Why?
| | Bias | 5 | 2022 | 218 | 0.400 |
Why?
| | Treatment Outcome | 9 | 2023 | 10811 | 0.390 |
Why?
| | Disease Progression | 15 | 2021 | 2757 | 0.390 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 57 | 0.380 |
Why?
| | Oncogenes | 1 | 2013 | 116 | 0.380 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.370 |
Why?
| | Animals | 33 | 2025 | 36940 | 0.370 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 530 | 0.360 |
Why?
| | Genome | 5 | 2017 | 300 | 0.360 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 6 | 0.360 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 596 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2531 | 0.350 |
Why?
| | Alzheimer Disease | 3 | 2015 | 560 | 0.340 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 17 | 0.340 |
Why?
| | Precision Medicine | 2 | 2025 | 429 | 0.340 |
Why?
| | Child, Preschool | 9 | 2025 | 11074 | 0.330 |
Why?
| | Adenocarcinoma | 4 | 2017 | 940 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2189 | 0.330 |
Why?
| | Models, Neurological | 2 | 2024 | 242 | 0.330 |
Why?
| | Antioxidants | 1 | 2014 | 584 | 0.330 |
Why?
| | Gene Expression | 3 | 2014 | 1502 | 0.320 |
Why?
| | Colorado | 6 | 2025 | 4565 | 0.320 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 265 | 0.320 |
Why?
| | Stem Cells | 3 | 2020 | 594 | 0.310 |
Why?
| | Signal Transduction | 10 | 2025 | 5079 | 0.310 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 112 | 0.310 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 29 | 0.310 |
Why?
| | Gene Dosage | 1 | 2010 | 140 | 0.310 |
Why?
| | Aged | 29 | 2024 | 23961 | 0.310 |
Why?
| | Risk Factors | 14 | 2025 | 10388 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 138 | 0.300 |
Why?
| | Middle Aged | 34 | 2024 | 33479 | 0.300 |
Why?
| | Child | 16 | 2025 | 21935 | 0.300 |
Why?
| | Liver Neoplasms | 1 | 2015 | 786 | 0.300 |
Why?
| | Protein Array Analysis | 8 | 2009 | 57 | 0.290 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 286 | 0.290 |
Why?
| | Proteomics | 5 | 2009 | 1111 | 0.290 |
Why?
| | Emigration and Immigration | 1 | 2008 | 46 | 0.290 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.290 |
Why?
| | Carcinoma | 2 | 2007 | 240 | 0.290 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.290 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 674 | 0.280 |
Why?
| | Probability | 3 | 2021 | 304 | 0.280 |
Why?
| | Chromosome Mapping | 6 | 2017 | 523 | 0.280 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 333 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1502 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 643 | 0.270 |
Why?
| | Flow Cytometry | 2 | 2022 | 1178 | 0.270 |
Why?
| | Research Design | 5 | 2021 | 1139 | 0.260 |
Why?
| | Tumor Burden | 1 | 2008 | 309 | 0.260 |
Why?
| | Adult | 27 | 2024 | 37929 | 0.260 |
Why?
| | Proteome | 3 | 2007 | 472 | 0.260 |
Why?
| | Pancreas | 2 | 2020 | 329 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 252 | 0.250 |
Why?
| | Monte Carlo Method | 4 | 2017 | 148 | 0.240 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1040 | 0.240 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 202 | 0.240 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 27 | 0.240 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1389 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2475 | 0.230 |
Why?
| | False Positive Reactions | 4 | 2012 | 115 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 95 | 0.230 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 506 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 539 | 0.230 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2139 | 0.230 |
Why?
| | Cell Nucleus | 2 | 2019 | 620 | 0.230 |
Why?
| | Replication Origin | 1 | 2004 | 19 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3566 | 0.220 |
Why?
| | Fever | 2 | 2023 | 306 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2426 | 0.220 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 65 | 0.220 |
Why?
| | Dengue Virus | 1 | 2024 | 52 | 0.220 |
Why?
| | Weather | 1 | 2024 | 40 | 0.220 |
Why?
| | Adolescent | 12 | 2025 | 21513 | 0.210 |
Why?
| | Data Curation | 1 | 2024 | 17 | 0.210 |
Why?
| | Leukemia | 1 | 2006 | 240 | 0.210 |
Why?
| | ROC Curve | 5 | 2020 | 554 | 0.210 |
Why?
| | Antigens | 1 | 2005 | 357 | 0.210 |
Why?
| | Dengue | 1 | 2024 | 80 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2007 | 771 | 0.210 |
Why?
| | Ligands | 2 | 2016 | 664 | 0.210 |
Why?
| | Cell Phone | 1 | 2024 | 76 | 0.210 |
Why?
| | Melanoma | 3 | 2005 | 760 | 0.210 |
Why?
| | Histones | 4 | 2020 | 636 | 0.210 |
Why?
| | Sample Size | 3 | 2008 | 125 | 0.210 |
Why?
| | Coculture Techniques | 1 | 2004 | 239 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1079 | 0.200 |
Why?
| | Staining and Labeling | 1 | 2023 | 150 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 1060 | 0.200 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 29 | 0.200 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.200 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 162 | 0.200 |
Why?
| | Carcinogens | 1 | 2003 | 125 | 0.200 |
Why?
| | Organometallic Compounds | 1 | 2023 | 111 | 0.200 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 176 | 0.200 |
Why?
| | Retina | 2 | 2016 | 298 | 0.200 |
Why?
| | Personality | 1 | 2004 | 132 | 0.200 |
Why?
| | Social Stigma | 1 | 2024 | 137 | 0.200 |
Why?
| | Emphysema | 1 | 2023 | 106 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 272 | 0.190 |
Why?
| | Biomedical Research | 2 | 2025 | 692 | 0.190 |
Why?
| | Neuroimaging | 2 | 2015 | 259 | 0.190 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2253 | 0.190 |
Why?
| | Parasites | 1 | 2022 | 50 | 0.190 |
Why?
| | Estrogens | 2 | 2019 | 367 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 123 | 0.190 |
Why?
| | Construction Materials | 1 | 2021 | 15 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1250 | 0.180 |
Why?
| | Infant | 3 | 2024 | 9465 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2691 | 0.180 |
Why?
| | Brain Waves | 1 | 2021 | 33 | 0.180 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.180 |
Why?
| | Young Adult | 11 | 2024 | 13209 | 0.180 |
Why?
| | Zebrafish | 2 | 2016 | 499 | 0.180 |
Why?
| | Analysis of Variance | 4 | 2024 | 1316 | 0.180 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 50 | 0.180 |
Why?
| | Epilepsy | 2 | 2021 | 333 | 0.180 |
Why?
| | Mutation, Missense | 2 | 2016 | 341 | 0.180 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 242 | 0.180 |
Why?
| | Receptors, Androgen | 2 | 2021 | 150 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 660 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1496 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 606 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1916 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 102 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 377 | 0.170 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 225 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 288 | 0.170 |
Why?
| | Peptides | 4 | 2007 | 985 | 0.170 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 73 | 0.170 |
Why?
| | RNA, Messenger | 8 | 2024 | 2833 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 397 | 0.160 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 102 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 822 | 0.160 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 159 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 120 | 0.160 |
Why?
| | Exome | 2 | 2018 | 231 | 0.160 |
Why?
| | Androgens | 3 | 2012 | 187 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 806 | 0.160 |
Why?
| | Artificial Intelligence | 3 | 2008 | 279 | 0.160 |
Why?
| | Phosphorylation | 3 | 2019 | 1759 | 0.160 |
Why?
| | Disease Reservoirs | 1 | 2019 | 21 | 0.160 |
Why?
| | Hospital Mortality | 1 | 2024 | 911 | 0.160 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 532 | 0.160 |
Why?
| | Protein Binding | 5 | 2019 | 2224 | 0.160 |
Why?
| | Tretinoin | 1 | 2020 | 123 | 0.160 |
Why?
| | Mice | 16 | 2025 | 17787 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4030 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 40 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 55 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 26 | 0.150 |
Why?
| | Disease | 1 | 2019 | 98 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 62 | 0.150 |
Why?
| | Pilot Projects | 2 | 2021 | 1710 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2900 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2607 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 94 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2020 | 169 | 0.150 |
Why?
| | Pituitary Gland | 2 | 2009 | 148 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2024 | 827 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 62 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 455 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 861 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 344 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 712 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2022 | 316 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 118 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 86 | 0.140 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 938 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 117 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | Pregnancy | 5 | 2019 | 6763 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 82 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 622 | 0.140 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 22 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 164 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 97 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 188 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5472 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 106 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 658 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 153 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 139 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 843 | 0.130 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1457 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 76 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2017 | 195 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 267 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 5 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 175 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 43 | 0.130 |
Why?
| | RNA, Viral | 2 | 2024 | 656 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 3 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 2 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 250 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 21 | 0.130 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 156 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 638 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2019 | 491 | 0.130 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 10 | 0.130 |
Why?
| | Mosquito Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 41 | 0.130 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 955 | 0.130 |
Why?
| | Anus Neoplasms | 1 | 2016 | 33 | 0.130 |
Why?
| | Oxides | 1 | 2016 | 46 | 0.130 |
Why?
| | Transcription Factors | 6 | 2017 | 1719 | 0.130 |
Why?
| | ErbB Receptors | 2 | 2012 | 614 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 889 | 0.120 |
Why?
| | Anesthesiologists | 1 | 2016 | 28 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 339 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 404 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 186 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 217 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 378 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 578 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 90 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 364 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 125 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2021 | 493 | 0.120 |
Why?
| | Aged, 80 and over | 13 | 2022 | 7635 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 97 | 0.120 |
Why?
| | Cough | 2 | 2007 | 122 | 0.120 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1291 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 377 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 327 | 0.120 |
Why?
| | Oleic Acid | 1 | 2015 | 40 | 0.120 |
Why?
| | Proteolysis | 1 | 2016 | 177 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 3958 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 315 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 388 | 0.120 |
Why?
| | HIV Infections | 3 | 2022 | 2836 | 0.120 |
Why?
| | Air Pollution | 2 | 2017 | 316 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 439 | 0.110 |
Why?
| | Risk | 1 | 2017 | 912 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 806 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 285 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 403 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2186 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 1991 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 697 | 0.110 |
Why?
| | Time Factors | 5 | 2016 | 6828 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.110 |
Why?
| | Ants | 1 | 2014 | 25 | 0.110 |
Why?
| | Catalysis | 2 | 2012 | 307 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 13 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 451 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2019 | 539 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 356 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 55 | 0.110 |
Why?
| | Benzothiazoles | 1 | 2014 | 33 | 0.110 |
Why?
| | Survival Rate | 4 | 2019 | 1972 | 0.110 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 88 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2844 | 0.110 |
Why?
| | Chromatography, Gel | 1 | 2014 | 127 | 0.110 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 16 | 0.110 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3412 | 0.110 |
Why?
| | Amphotericin B | 1 | 2013 | 31 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 88 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 230 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 141 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 143 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1070 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 129 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 398 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5742 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 622 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5131 | 0.100 |
Why?
| | Estradiol | 2 | 2014 | 521 | 0.100 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.100 |
Why?
| | Interleukin-2 | 2 | 2025 | 455 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 294 | 0.090 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2024 | 105 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 8 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1272 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 79 | 0.090 |
Why?
| | Silver | 1 | 2012 | 38 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 900 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 107 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1069 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 872 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 427 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 195 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 13 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1167 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 976 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 15 | 0.090 |
Why?
| | Motion | 1 | 2012 | 99 | 0.090 |
Why?
| | Heme | 1 | 2012 | 78 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 91 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 13 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 95 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 11 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 984 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 207 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 98 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 225 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 346 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 692 | 0.090 |
Why?
| | Lung | 2 | 2023 | 4060 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 180 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3295 | 0.090 |
Why?
| | Chemokines | 1 | 2011 | 228 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 510 | 0.090 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 847 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1101 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1381 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1077 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 148 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 88 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 563 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1060 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Prevalence | 2 | 2015 | 2734 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 413 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 298 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.080 |
Why?
| | Autoimmunity | 2 | 2025 | 908 | 0.080 |
Why?
| | CpG Islands | 2 | 2023 | 157 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 93 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 127 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 951 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 92 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15657 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 53 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 778 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 102 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 203 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 625 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 45 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 38 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 128 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1570 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 329 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 87 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 698 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1009 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 237 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 390 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 33 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1313 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 48 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 190 | 0.070 |
Why?
| | Self Concept | 1 | 2009 | 253 | 0.070 |
Why?
| | Nails | 1 | 2007 | 12 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 352 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 118 | 0.070 |
Why?
| | Exercise | 1 | 2018 | 2057 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1289 | 0.070 |
Why?
| | Nepal | 2 | 2016 | 30 | 0.070 |
Why?
| | Genome, Bacterial | 2 | 2006 | 142 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 425 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3715 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 74 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 59 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 123 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 337 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 42 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 64 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 570 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 63 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 30 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 617 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 32 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 26 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 146 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2553 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 42 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 189 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 59 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 380 | 0.060 |
Why?
| | United States | 7 | 2018 | 14841 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 163 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 686 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 385 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 98 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 56 | 0.060 |
Why?
| | Family Characteristics | 2 | 2016 | 191 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 109 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 367 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 314 | 0.060 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 159 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 672 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 374 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1062 | 0.060 |
Why?
| | Poisson Distribution | 1 | 2004 | 75 | 0.060 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 268 | 0.060 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 55 | 0.060 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 19 | 0.060 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.060 |
Why?
| | Culture Techniques | 1 | 2004 | 81 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 311 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 390 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 370 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 172 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 165 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 514 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 59 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2389 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 75 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 860 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 139 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 214 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1639 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 42 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 434 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 318 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 67 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 133 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 83 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 71 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 828 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1430 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 289 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 2295 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1547 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 129 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 175 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 137 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 319 | 0.050 |
Why?
| | Breast | 1 | 2003 | 151 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 852 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 37 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 130 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 135 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2199 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 327 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 106 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 385 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 249 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 718 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 97 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5757 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1164 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 186 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 31 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 53 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 180 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 283 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 40 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1096 | 0.050 |
Why?
| | Seasons | 1 | 2024 | 547 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 24 | 0.040 |
Why?
| | Entropy | 1 | 2021 | 41 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 37 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 417 | 0.040 |
Why?
| | Japan | 1 | 2021 | 115 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2057 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 565 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 493 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 460 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 158 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 388 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 204 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 43 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 29 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 25 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 61 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 268 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 558 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 893 | 0.040 |
Why?
| | Policy | 1 | 2021 | 150 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 549 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 38 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 67 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 266 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 232 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 308 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 496 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 97 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 135 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 13 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 16 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 2892 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 22 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 423 | 0.040 |
Why?
| | Skin | 2 | 2017 | 752 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 24 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4295 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1303 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 94 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 347 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 718 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 789 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 440 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 332 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 227 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 267 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 243 | 0.040 |
Why?
| | Malaria | 1 | 2019 | 63 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 426 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 847 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 660 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 44 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 226 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 430 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 289 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1468 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 176 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3015 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 49 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 31 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 85 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 109 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 996 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 15 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 70 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 211 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 13 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 16 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 95 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 86 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 142 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 66 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 162 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 175 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 493 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 840 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 389 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 51 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 96 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 279 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 730 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 203 | 0.030 |
Why?
| | Family | 1 | 2019 | 671 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1153 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 164 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 305 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 967 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 184 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5647 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 70 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1023 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 315 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 137 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 855 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 341 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 99 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 673 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 29 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 39 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 230 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 436 | 0.030 |
Why?
| | Demography | 1 | 2014 | 291 | 0.030 |
Why?
| | North America | 1 | 2014 | 313 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 305 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 114 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 585 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 192 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2847 | 0.030 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 413 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 812 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2085 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2069 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 92 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 70 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 144 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 34 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 98 | 0.020 |
Why?
| | Methane | 1 | 2012 | 49 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 230 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 316 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7604 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 251 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 827 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1397 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1287 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 32 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2409 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 374 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 691 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 36 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 372 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 48 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1786 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 118 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 328 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2129 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1692 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 26 | 0.020 |
Why?
| | Genes | 1 | 2008 | 230 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 327 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 249 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 515 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 50 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 173 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 931 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 433 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 257 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 384 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 23 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 21 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 213 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 28 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 49 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1317 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 30 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 33 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 208 | 0.020 |
Why?
| | Television | 1 | 2007 | 75 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 804 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1091 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 105 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 135 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 78 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 190 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 85 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 92 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 167 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1242 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1353 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1329 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 518 | 0.020 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.020 |
Why?
| | Databases as Topic | 1 | 2005 | 67 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 60 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 78 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 51 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 60 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 366 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 95 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 55 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 41 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 353 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 430 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 204 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 148 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 350 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 91 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 273 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 27 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 558 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 19 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 86 | 0.010 |
Why?
| | Internet | 1 | 2007 | 655 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 66 | 0.010 |
Why?
| | California | 1 | 2003 | 431 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 601 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 202 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 547 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1622 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 648 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 879 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 945 | 0.010 |
Why?
| | RNA | 1 | 2005 | 921 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2031 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1120 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1864 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|